Abstract
Celiac disease (CD) and irritable bowel syndrome (IBS) are two disorders that share common features, such as similar symptoms and autoimmune involvement. However, the molecular genetic mechanisms underlying their pathogenesis remain unclear. An in silico systems biology approach was performed to analyze the RNA-seq (GSE146190 and GSE166869) and microarray data (GSE164883 and GSE63379) of both diseases. Gene ontology was first identified, followed by transcriptional factors and miRNAs that regulate the mutual genes by Enrichr platform. Moreover, a protein-protein interaction network of the shared genes was constructed, and the hub genes were identified using Network Analyst and Cytoscape. Finally, the tertiary structure of the most significant hub gene product was downloaded and screened against approved drugs using DrupRep server for drug repurposing. Four hundred thirty-nine shared genes between CD and IBS were revealed, which were mainly involved in response to stimulus, proliferation regulation, metabolism of small molecules, and apoptosis. RARG, NFE2L2, VDR, NCOA1, and RXRA were the top five transcription factors that regulated these genes, whereas hsa-miR-4632-3p, hsa-miR-598-5p, hsa-miR-7108-3p, and hsa-miR-29b-3p were the top five miRNAs. SRC, STAT1, CCNB1, CDK1, CD44, RRM2, ERBB2, BUB1B, KIF11, and TOP2A were ranked as the Top 10 hub genes by the PPI network analysis. Temoporfin, rimegepant, and eltrombopag were suggested as the top three lead candidates by the virtual screening against SRC with binding affinities of -11.1, 10.9, and -10.8 kcal/mol, respectively. These drugs are potential SRC inhibitors that warrant further experimental validation. Novel insights into the molecular genetic mechanisms of CD and IBS and new therapeutic avenues for these disorders were provided by this study.